We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
Read MoreHide Full Article
Key Takeaways
Boston Scientific's ICVT sales rose 15%, led by double-digit growth in coronary therapies.
BSX plans to launch its SEISMIQ 4CE catheter in the first half of 2027 after positive trial results.
BSX's MiRus investment and pending Penumbra deal could expand its long-term growth opportunities.
Boston Scientific (BSX - Free Report) saw continued strength in its Interventional Cardiology and Vascular Therapies (“ICVT”) business in the second quarter of 2026, with sales up 15% year over year. Interventional Cardiology led the performance, benefiting from double-digit growth in coronary therapies, with continued strength in Drug-Coated Balloon, imaging and complex Percutaneous Coronary Intervention. Management expects ICVT to be Boston Scientific’s strongest growth drivers in the coming years.
In May, the company presented data from the FRACTURE trial, studying its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter, in a late-breaking trial session at the EuroPCR 2026 congress. The trial met all endpoints, demonstrating high rates of freedom from major adverse cardiac events at 30 days and procedural success in patients with severely calcified coronary artery disease. Boston Scientific expects to launch the device in the first half of 2027.
The company also invested nearly $1.5 billion for an approximately 34% equity stake in MiRus LLC, developer of the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (“TAVR”) system. This agreement includes an exclusive option to acquire the MiRus TAVR system, subject to additional payments and certain milestones. Backed by years of research and proprietary technology, the SIEGEL valve’s unique design and impressive early clinical results may set it apart from currently available technologies.
In addition, enrollment is advancing in the THRIVE trial, which is evaluating the TIVUS Ultrasound System for renal denervation in the treatment of hypertension. The technology is expected to reach the market in 2028. Meanwhile, Vascular Therapies sales were led by broader adoption of Varithena and the drug-eluting portfolio. The SEISMIQ peripheral IVL launch is gaining a strong reception for its clinical differentiation as supply continues to ramp up.
The pending Penumbra acquisition could further expand BSX’s opportunities. The deal is nearing completion, subject to remaining regulatory clearances, and is expected to bolster the company’s long-term growth profile.
BSX Peer Update
Medtronic (MDT - Free Report) is investing approximately $700 million in Cornerstone Robotics as it expands presence in surgical robotics. Under the partnership, Medtronic will distribute Cornerstone’s Sentire system in select markets outside the United States where it has regulatory approval, alongside its own Hugo robotic-assisted surgery system. Medtronic also announced a strategic investment in Pi-Cardia Ltd., under which it will invest up to $80 million and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027.
Stryker (SYK - Free Report) has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength. The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.
BSX Price Performance, Valuation and Estimates
Year to date, Boston Scientific’s shares have plunged 50.7% compared with the industry’s 16.6% decline.
Image Source: Zacks Investment Research
Boston Scientific currently trades at a forward, five-year Price-to-Sales (P/S) ratio of 3.09, above the industry average of 2.24.
Image Source: Zacks Investment Research
The company’s earnings estimates have been steadily revised downward over the past three months.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #5 (Strong Sell).
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
Key Takeaways
Boston Scientific (BSX - Free Report) saw continued strength in its Interventional Cardiology and Vascular Therapies (“ICVT”) business in the second quarter of 2026, with sales up 15% year over year. Interventional Cardiology led the performance, benefiting from double-digit growth in coronary therapies, with continued strength in Drug-Coated Balloon, imaging and complex Percutaneous Coronary Intervention. Management expects ICVT to be Boston Scientific’s strongest growth drivers in the coming years.
In May, the company presented data from the FRACTURE trial, studying its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter, in a late-breaking trial session at the EuroPCR 2026 congress. The trial met all endpoints, demonstrating high rates of freedom from major adverse cardiac events at 30 days and procedural success in patients with severely calcified coronary artery disease. Boston Scientific expects to launch the device in the first half of 2027.
The company also invested nearly $1.5 billion for an approximately 34% equity stake in MiRus LLC, developer of the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (“TAVR”) system. This agreement includes an exclusive option to acquire the MiRus TAVR system, subject to additional payments and certain milestones. Backed by years of research and proprietary technology, the SIEGEL valve’s unique design and impressive early clinical results may set it apart from currently available technologies.
In addition, enrollment is advancing in the THRIVE trial, which is evaluating the TIVUS Ultrasound System for renal denervation in the treatment of hypertension. The technology is expected to reach the market in 2028. Meanwhile, Vascular Therapies sales were led by broader adoption of Varithena and the drug-eluting portfolio. The SEISMIQ peripheral IVL launch is gaining a strong reception for its clinical differentiation as supply continues to ramp up.
The pending Penumbra acquisition could further expand BSX’s opportunities. The deal is nearing completion, subject to remaining regulatory clearances, and is expected to bolster the company’s long-term growth profile.
BSX Peer Update
Medtronic (MDT - Free Report) is investing approximately $700 million in Cornerstone Robotics as it expands presence in surgical robotics. Under the partnership, Medtronic will distribute Cornerstone’s Sentire system in select markets outside the United States where it has regulatory approval, alongside its own Hugo robotic-assisted surgery system. Medtronic also announced a strategic investment in Pi-Cardia Ltd., under which it will invest up to $80 million and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027.
Stryker (SYK - Free Report) has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength. The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.
BSX Price Performance, Valuation and Estimates
Year to date, Boston Scientific’s shares have plunged 50.7% compared with the industry’s 16.6% decline.
Image Source: Zacks Investment Research
Boston Scientific currently trades at a forward, five-year Price-to-Sales (P/S) ratio of 3.09, above the industry average of 2.24.
Image Source: Zacks Investment Research
The company’s earnings estimates have been steadily revised downward over the past three months.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.